How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

92 results for

Kayexalate

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

21. Open-label Safety of Sodium Zirconium Cyclosilicate for up to 12 Months in Japanese Subjects With Hyperkalemia

to first dose of ZS. Patients treated with resins (such as sevelamer hydrochloride, sodium polystyrene sulfonate [SPS; e.g. Kayexalate®] or calcium polystyrene sulfonate [CPS]), calcium acetate, calcium carbonate, or lanthanum carbonate, within 7 days prior to the first dose of study drug. Washout of SPS and CPS for 7 days (or longer) prior to the first dose of ZS is allowed, if termination of CPS or SPS is judged to be clinically acceptable by the investigator. Documented informed consent has

2017 Clinical Trials

22. Pharmacokinetic Study of Tacrolimus and Mycophenolate Mofetil in Kidney Transplant Recipients With Hyperkalemia Receiving Patiromer

with the study. Kidney transplant recipient. Must be receiving MMF for maintenance immunosuppression Must be receiving tacrolimus for maintenance immunosuppression Subjects must have hyperkalemia (serum potassium ≥ 5.0 mEq/L and ≤ 6.0 mEq/L). Prior to enrollment, subjects must be taking a steady dose of tacrolimus for 3 days. Exclusion Criteria: Use of Kayexalate 1 day prior to screening visit. Serum potassium level of greater than 6.0 mEq/L at screening. Serum magnesium level of less than 1.0mg/dL

2017 Clinical Trials

23. LITFL Review 303

-sized chunk of Global FOAM. The Most Fair Dinkum Ripper Beauts of the Week Kenneth Palmer from Karolinska shares his in a podcast from the Maryland CCProject. [SO] The Best of Emergency Medicine We’ve known for some time that Kayexalate is generally ineffective in our patients, and comes with some untoward side effects. But an important piece from PulmCCM reveals that ! [RP] ERCast podcast on reviews recent articles on abscess, c-spine clearance in intoxicated patients, lytics in PE and much, much

2017 Life in the Fast Lane Blog

24. New drugs for hyperkalemia

. And these patients have an absolute indication for an ACE-I or ARB. Thus, we have a conundrum. How do we successfully treat their systolic dysfunction or progressive CKD. Drug companies see an niche. Sodium polysterene (Kayexalate) is not adequate due to dangerous side effects. Patiromer (Valtessa) was released first, now this new option. What will be their roles? What will be the pricing? This is all interesting, and we will follow the indications for its use with interest. Share this: Like this: Like Loading

2018 db's Medical Rants blog

25. A Case of Hypophosphatemia with Increased Urinary Excretion of Phosphorus Associated with Ibrutinib Full Text available with Trip Pro

/dl) and potassium (reaching a peak of 6.5 mEq/l). Uric acid and calcium levels were normal. The patient developed hypophosphatemia (prior to initiation of therapy the serum phosphorus was 2.9 mg/dl). No metabolic acidosis was noted. Urinalysis showed no glucosuria or proteinuria. Urinary fraction of excretion of phosphate was found to be 345% (normal <5%). Because of these changes, ibrutinib was held, and the patient was given kayexalate. Serum potassium normalized. Serum phosphorus was checked

2016 Case reports in oncology

26. Novel kyperkalemia treatments – practical points

Novel kyperkalemia treatments – practical points Renal Fellow Network: Novel hyperkalemia treatments – practical points | | | | | Sunday, January 24, 2016 Novel hyperkalemia treatments – practical points I was quite excited to see the development of novel agents to help us manage hyperkalemia in our kidney patients in place of kayexalate, which is extremely unpleasant for patients, is associated with diarrhea and have reported severe side effects such as intestinal necrosis. As previously (...) and constipation. Duration of trials were up to 52 weeks. is a crystalline compound of zirconium silicate that exchanges Na+/H+ for K+. Based on its mechanism of action, patients will have about 300mg of extra Na+ intake per day (Kayexalate has the same issue). The main side effect of ZS9 was edema (~7%). Duration of trial with ZS-9 was only 4 weeks. FDA has not approved ZS9 yet but it is likely that once approved, it will be the leading drug in the market, especially if the black box from FDA remains

2016 Renal Fellow Network

27. Colesevelam and Colestipol: Novel Medication Resins in the Gastrointestinal Tract. (Abstract)

) and lacked internal "fish-scales." To validate these observations, respective medications were submitted for histologic processing; the processed medications were identical to those in the patient specimens. Rare, irregular "fracture" lines presented diagnostic pitfalls by mimicking the true "fish-scales" of Kayexalate and sevelamer. Clues to the correct identification of BAS include recognition that the "fracture" lines were subtle, irregular, and restricted to large fragments or thick sections, likely (...) representing a processing artifact. Moreover, Kayexalate is violet on H&E and black on acid fast bacillus, and sevelamer characteristically displays a 2-tone color on H&E and is magenta on acid fast bacillus. An association with inflammatory injury was seen (15/26). We believe that the BAS are innocent bystanders in complicated patients, although we cannot exclude their ability to cause mucosal injury in specific settings.

2014 American Journal of Surgical Pathology

28. Safety & Efficacy of Zirconium Silicate Dosed for 28 Days in Hyperkalemia.

of severe leukocytosis or thrombocytosis. Subjects treated with lactulose, Xifaxan or other non-absorbed antibiotics for hyperammonemia within 7 days prior to the first dose of study drug. Subjects treated with resins (such as sevelamer acetate or sodium polystyrene sulfonate [SPS; e.g. Kayexalate®]), calcium acetate, calcium carbonate, or lanthanum carbonate, within 7 days prior to the first dose of study drug. Subjects with a life expectancy of less than 3 months. Subjects who are severely physically

2014 Clinical Trials

29. Efficacy of Sodium Polystyrene Sulfonate in the Treatment of Hyperkaliemia in Pre-dialysis Patients

/treatment Active Comparator: Sodium Polystyrene Sulfonate 30 g sodium polystyrene sulfonate powder, mixed with water qs ad 150 ml, taken PO once daily for seven days Drug: Sodium polystyrene sulfonate Other Names: SPS Kayexalate Solystat Placebo Comparator: Lactose with carob gum 30 g placebo powder, mixed with water qs ad 150 ml, taken PO once daily for seven days Drug: Lactose with carob gum Other Name: Placebo Outcome Measures Go to Primary Outcome Measures : Change in serum potassium levels from (...) provided by Dr. Vincent Pichette, Maisonneuve-Rosemont Hospital: Sodium Polystyrene Sulfonate Kayexalate Pre-dialysis Outpatients Hyperkalemia Chronic kidney failure Potassium Additional relevant MeSH terms: Layout table for MeSH terms Renal Insufficiency Hyperkalemia Kidney Failure, Chronic Kidney Diseases Urologic Diseases Water-Electrolyte Imbalance Metabolic Diseases Renal Insufficiency, Chronic Polystyrene sulfonic acid Chelating Agents Sequestering Agents Molecular Mechanisms of Pharmacological

2014 Clinical Trials

30. Evaluation of Gut Bacteria in Patients With Polycystic Kidney Disease

. Patients with PKD. Patients are able to understand and give consent. Exclusion Criteria: Patient on antibiotics or vitamin supplement (except vitamin D analogs) in the last three months. Advanced liver disease, advanced cardiovascular disease, heart failure with EF < 30%, and autoimmune disease. The use of chemotherapy, antibiotics, immunosuppressive medications, probiotics, and steroid in the last three month. Intravenous or oral iron supplementation, laxatives, and kayexalate in the last month

2014 Clinical Trials

31. Open-label Safety and Efficacy of Sodium Zirconium Cyclosilicate for up to 12 Months Including Randomized Withdrawal

or traumatic venipuncture, or history of severe leukocytosis or thrombocytosis. Subjects treated with lactulose, rifaximin, or other non-absorbed antibiotics for hyperammonemia within 7 days prior to first dose of ZS on Acute Phase Study Day 1. Subjects treated with sodium polystyrene sulfonate (SPS; eg, Kayexalate®) or calcium polystyrene sulfonate (eg, Resonium®) within 3 days prior to first dose of ZS on Acute Phase Study Day 1. Subjects with a life expectancy of less than 12 months. Subjects who

2014 Clinical Trials

32. Monocentric STUDY, Randomised Double Blinded (Healthy Subjects, or Transversal (Patients With Gitelman Syndrome)

will be submitted twice to two periods of normal Na+/ high K+ diet (control period) followed by a normal Na+/ low K+ diet sustained by a pharmacological treatment with Kayexalate (K+-depleted condition). The subjects will be treated with either RU486 or a placebo, according to a randomization. The adrenal response will be evaluated after stimulation by Synacthen at baseline and at the end of each experimental period. A Synacthen test will be also done in 10 patients suffering of chronic hypokalemia linked

2014 Clinical Trials

33. Hyperkalemia (Diagnosis)

(Florinef), in patients with hyporeninemia or hypoaldosteronism or solid organ transplant patients with chronic hyperkalemia from calcineurin inhibitor use Potassiuim binders include cation exchange resins such as sodium polystyrene sulfonate (SPS; Kayexalate), patiromer, or sodium zirconium cyclosilicate (Lokelma); an SPS retention enema may be used for hyperkalemic emergencies, oral products have slower onset of action, but may be considered for patients with advanced renal failure who are not yet

2014 eMedicine.com

34. Metabolic Alkalosis (Diagnosis)

with a cation-exchange resin (eg, sodium polystyrene sulfonate [Kayexalate]); the resin binds the cation, leaving bicarbonate unbound. Thiazides and loop diuretics enhance sodium chloride excretion in the distal convoluted tubule and the thick ascending loop, respectively. These agents cause metabolic alkalosis by chloride depletion and by increased delivery of sodium ions to the collecting duct, which enhances potassium ion and hydrogen ion secretion. Volume depletion also stimulates aldosterone secretion

2014 eMedicine.com

35. Metabolic Alkalosis (Overview)

with a cation-exchange resin (eg, sodium polystyrene sulfonate [Kayexalate]); the resin binds the cation, leaving bicarbonate unbound. Thiazides and loop diuretics enhance sodium chloride excretion in the distal convoluted tubule and the thick ascending loop, respectively. These agents cause metabolic alkalosis by chloride depletion and by increased delivery of sodium ions to the collecting duct, which enhances potassium ion and hydrogen ion secretion. Volume depletion also stimulates aldosterone secretion

2014 eMedicine.com

36. Hyperkalemia (Overview)

(Florinef), in patients with hyporeninemia or hypoaldosteronism or solid organ transplant patients with chronic hyperkalemia from calcineurin inhibitor use Potassiuim binders include cation exchange resins such as sodium polystyrene sulfonate (SPS; Kayexalate), patiromer, or sodium zirconium cyclosilicate (Lokelma); an SPS retention enema may be used for hyperkalemic emergencies, oral products have slower onset of action, but may be considered for patients with advanced renal failure who are not yet

2014 eMedicine.com

37. Hyperkalemia (Treatment)

, Collingridge DS, Harmston GE. Fludrocortisone is effective in the management of tacrolimus-induced hyperkalemia in liver transplant recipients. Transplant Proc . 2011 Sep. 43(7):2664-8. . Rogers FB, Li SC. Acute colonic necrosis associated with sodium polystyrene sulfonate (Kayexalate) enemas in a critically ill patient: case report and review of the literature. J Trauma . 2001 Aug. 51(2):395-7. . McGowan CE, Saha S, Chu G, Resnick MB, Moss SF. Intestinal necrosis due to sodium polystyrene sulfonate (...) (Kayexalate) in sorbitol. South Med J . 2009 May. 102(5):493-7. . . US Food and Drug Administration. Safety: Kayexalate (sodium polystyrene sulfonate) powder. Available at . Accessed: October 5, 2015. Harel Z, Harel S, Shah PS, Wald R, Perl J, Bell CM. Gastrointestinal adverse events with sodium polystyrene sulfonate (Kayexalate) use: a systematic review. Am J Med . 2013 Mar. 126(3):264.e9-24. . Bakris GL, Pitt B, Weir MR, Freeman MW, Mayo MR, Garza D, et al. Effect of Patiromer on Serum Potassium Level

2014 eMedicine.com

38. Hyperchloremic Acidosis (Treatment)

, ACE inhibitors, potassium-sparing diuretics, beta blockers) must be avoided. Cation-exchange resins (eg, sodium polystyrene sulfonate [Kayexalate], alkalinizing salts) can be helpful in controlling hyperkalemia. In many instances, careful evaluation of iatrogenic offenders (eg, beta blockers, ACE inhibitors) can explain persistently high potassium levels in the absence of moderate to severe renal failure. Previous Next: Avoidance and Prevention A variety of drugs can aggravate or cause

2014 eMedicine.com

39. Uremia (Treatment)

to stabilize cardiac membranes, bicarbonate, insulin and glucose administration, or inhaled or intravenous beta agonists. Nonemergent hyperkalemia can be treated with oral potassium binders (eg, sodium polystyrene sulfonate [Kayexalate]). Correction of acidemia may improve the potassium balance. In addition, it is imperative to discontinue any medicine that might be contributing to the hyperkalemia, including the following: Angiotensin-converting enzyme (ACE) inhibitors Angiotensin-receptor blockers (ARBs

2014 eMedicine.com

40. Gastritis, Acute (Overview)

. Note the following: Drugs - NSAIDs, such as aspirin, ibuprofen, and naproxen; cocaine; iron; colchicine, when at toxic levels, as in patients with failing renal or hepatic function; kayexalate; chemotherapeutic agents, such as mitomycin C, 5-fluoro-2-deoxyuridine, and floxuridine Potent alcoholic beverages, such as whisky, vodka, and gin Bacterial infections - H pylori (most frequent), H heilmanii (rare), streptococci (rare), staphylococci (rare), Proteus species (rare), Clostridium species (rare

2014 eMedicine.com

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>